Cholesterol efflux from Fu5AH hepatoma cells induced by plasma of subjects with or without coronary artery disease and non-insulin-dependent diabetes: Importance of LpA-I:A-II particles and phospholipid transfer protein

Atherosclerosis

Volumn 127, Issue 2, 1996, Pages 245-253

  Syvänne, Mikko ^a   Castro, Graciela ^b   Dengremont, Catherine ^b   De Geitere, Catherine ^b   Jauhiainen, Matti ^c   Ehnholm, Christian ^c   Michelagnoli, Silvia ^d   Franceschini, Guido ^d   Kahri, Juhani ^a   Taskinen, Marja Riitta ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b INSTITUT PASTEUR DE LILLE   (France)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

apolipoprotein specific particles; high density lipoproteins; in vitro cholesterol efflux; lecithin cholesteryl acyltransferase; lipid transfer proteins; reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID TRANSFER PROTEIN;

ADULT; ANIMAL CELL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CORONARY ARTERY DISEASE; HEPATOMA CELL; HUMAN; LIPID METABOLISM; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLASMA; PRIORITY JOURNAL; RAT;

AGED; ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN A-II; BIOLOGICAL TRANSPORT; CARRIER PROTEINS; CHOLESTEROL; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; HUMANS; IMMUNORADIOMETRIC ASSAY; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PHOSPHOLIPID TRANSFER PROTEINS; RATS; TUMOR CELLS, CULTURED;

EID: 0030595989     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(96)05962-X     Document Type: Article

References (57)

1. [1] Franceschini G, Maderna P, Sirtori CR. Reverse cholesterol transport: physiology and pharmacology. Atherosclerosis 1991;88:99-107.
2. [2] Tall AR. Plasma high density lipoproteins: metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-384.
3. [3] Gordon DJ, Rifkind BM. High-density lipoprotein - the clinical implications of recent studies. N Engl J Med 1989;321:1311-316.
4. [4] Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-β-migrating high-density lipoprotein. Biochemistry 1988;27:25-29.
5. [5] Von Eckardstein A, Huang Y, Assman G. Physiological role and clinical relevance of high-density lipoprotein subclasses. Curr Opin Lipidol 1994;5:404-416.
6. [6] Barter P. High-density lipoproteins and reverse cholesterol transport. Curr Opin Lipidol 1993;4:210-217.
7. [7] Pyörälä K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987;3:463-524.
8. [8] Taskinen M-R. Hyperlipidaemia in diabetes. Baillieres Clin Endocrinol Metab 1990;4:743-775.
9. [9] Syvänne M, Kahri J, Virtanen KS, Taskinen M-R. HDLs containing apolipoproteins A-I and A-II (LpA-I:A-II) as markers of coronary artery disease in men with non-insulin-dependent diabetes mellitus. Circulation 1995;92:364-370.
10. [10] Cavallero E, Brites F, Delfly B et al. Abnormal reverse cholesterol transport in controlled type II diabetic patients: studies on fasting and postprandial LpA-I particles. Arterioscler Thromb Vasc Biol 1995;15:2130-2135.
11. [11] Fruchart JC, De Geteire C, Delfly B, Castro GR. Apolipoprotein A-I-containing particles and reverse cholesterol transport: evidence for connection between cholesterol efflux and atherosclerosis risk. Atherosclerosis 1994;110(Suppl):S35-S39.
12. [12] De la Llera Moya M, Atger V, Paul JL et al. A cell culture system for screening human serum for ability to promote cellular cholesterol efflux: relations between serum components and efflux, esterification, and transfer. Arterioscler Thromb 1994;14:1056-1065.
13. [13] Lagrost L, Dengremont C, Athias A et al. Modulation of cholesterol efflux from Fu5AH hepatoma cells by the apolipoprotein content of high density lipoprotein particles: particles containing various proportions of apolipoproteins A-I and A-II. J Biol Chem 1995;270:13004-13009.
14. [14] Syvänne M, Ahola M, Lahdenperä S, Kahri J, Virtanen KS, Taskinen M-R. High density lipoprotein subfractions in non-insulin-dependent diabetes mellitus and coronary artery disease. J Lipid Res 1995;36:573-582.
15. [15] Taskinen M-R, Kuusi T, Helve E, Nikkilä E, Yki-Järvinen H. Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes. Arteriosclerosis 1988;8:168-177.
16. [16] Kashyap ML, Hynd BA, Robinson K. A rapid and simple method for measurement of total protein in the very low density lipoproteins by the Lowry assay. J Lipid Res 1980;21:491-495.
17. [17] Parra HJ, Mezdour H, Ghalim N, Bard JM, Fruchart J-C. Differential electroimmunoassay of human Lp A-I lipoprotein particles on ready-to-use plates. Clin Chem 1990;36:1431-1435.
18. [18] Huttunen JK, Ehnholm C, Kinnunen PKJ, Nikkilä EA. An immunochemical method for the selective measurement of two triglyceride lipases in human postheparin plasma. Clin Chim Acta 1975;63:335-347.
19. [19] Groener JEM, Pelton RW, Kostner GM. Improved estimation of cholesteryl ester transfer/exchange activity in serum or plasma. Clin Chem 1986;32:283-286.
20. [20] Kahri J, Syvänne M, Taskinen M-R. Plasma cholesteryl ester transfer protein activity in non-insulin-dependent diabetic patients with and without coronary artery disease. Metabolism 1994;43:1498-1502.
21. [21] Murakami T, Michelagnoli S, Longhi R et al. Triglycerides are major determinants of cholesterol esterification/transfer and HDL remodeling in human plasma. Arterioscler Thromb Vasc Biol 1995;15:1819-1828.
22. [22] Jauhiainen M, Metso J, Pahlman R, Blomqvist S, van Tol A, Ehnholm C. Human plasma phospholipid transfer protein causes high density lipoprotein conversion. J Biol Chem 1993;268:4032-4036.
23. [23] Pussinen P, Jauhiainen M, Metso J, Tyynelä J, Ehnholm C. Pig plasma phospholipid transfer protein facilitates HDL interconversion. J Lipid Res 1995;36:975-985.
24. [24] Albers JJ, Wolfbauer G, Cheung MC et al. Functional expression of human and mouse plasma phospholipid transfer protein: effect of recombinant and plasma PLTP on HDL subspieces. Biochim Biophys Acta 1995;1258:27-34.
25. [25] Lusa S, Jauhiainen M, Metso J, Somerharju P, Ehnholm C. The mechanism of human plasma phospholipid transfer protein-induced enlargement of high-density lipoprotein particles: evidence for particle fusion. Biochem J 1996;313:275-282.
26. [26] Miller NE, la Ville A, Crook D. Direct evidence that reverse cholesterol transport is mediated by high-density lipoprotein in rabbit. Nature 1985;314:109-111.
27. [27] Badimon JJ, Badimon L, Galvez A, Dische R, Fuster V. High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. Lab Invest 1989;60:455-461.
28. [28] Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990;85:1234-1241.
29. [29] Duell PB, Oram JF, Bierman EL. Nonenzymatic glycosylation of HDL and impaired HDL-receptor-mediated cholesterol efflux. Diabetes 1991;40:377-384.
30. [30] Fievet C, Theret N, Shojaee N et al. Apolipoprotein A-I-containing particles and reverse cholesterol transport in IDDM. Diabetes 1992;41(Suppl 2):81-85.
31. [31] Brazg RL, Bierman EL. Insulin excess counteracts the effects of HDL on intracellular sterol accumulation in cultered human skin fibroblasts. Diabetologia 1993;36:942-947.
32. 2+-mediated oxidation. FEBS Lett 1992;314:199-202.
33. [33] Morel DW. Reduced cholesterol efflux to mildly oxidized high density lipoprotein. Biochem Biophys Res Commun 1994;200:408-416.
34. 165 → Arg). J Biol Chem 1993;268:2616-2622.
35. 11, particles. Biochem Biophys Res Commun 1987;142:63-69.
36. J-containing particles in cholesterol efflux from adipose cells. Atherosclerosis 1991;87:135-146.
37. [37] Huang Y, von Eckardstein A, Wu S, Assman G. Cholesterol efflux, cholesterol esterification, and cholesteryl ester transfer by LpA-I and LpA-I/A-II in native plasma. Arterioscler Thromb Vasc Biol 1995;15:1412-1418.
38. [38] Warden CH, Hedrick CC, Qiao J-H, Castellani LW, Lusis AJ. Atherosclerosis in transgenic mice overexpressing apolipoprotein A-II. Science 1993;261:469-472.
39. [39] Deeb SS, Takata K, Peng R, Kajiyama G, Albers JJ. A splice-junction mutation responsible for familial apolipoprotein A-II deficiency. Am J Hum Genet 1990;46:822-827.
40. [40] Johnson WJ, Kilsdonk EPC, van Tol A, Philips MC, Rothblat GH. Cholesterol efflux from cells to immunopurified subfractions of human high density lipoprotein: LP-AI and LP A-I/A-II. J Lipid Res 1991;32:1993-2000.
41. [41] Ohta T, Nakamura R, Ikeda Y et al. Differential effect of subspieces of lipoproteins containing apolipoprotein A-I on cholesterol efflux from cholesterol-loaded macrophages: functional correlation with lecithin:cholesterol acyltransferase. Biochim Biophys Acta 1992;1165:119-128.
42. [42] Oikawa S, Mendez AJ, Oram JF, Bierman EL, Cheung MC. Effects of high-density lipoprotein particles containing apo A-I, with or without apo A-II, on intracellular cholesterol efflux. Biochim Biophys Acta 1993;1165:327-334.
43. [43] Skarlatos SI, Duverger N, Rader D, Kruth HS. Cholesterol efflux from human monocyte-derived macrophages in the presence of LpA-I:A-II. Biochim Biophys Acta 1995;1270:19-25.
44. [44] Von Hodenberg E, Heinen S, Howell KE, Luley C, Kübler W, Bond HM. Cholesterol efflux from macrophages mediated by high-density lipoprotein subfractions, which differ principally in apolipoprotein A-I and apolipoprotein A-II ratios. Biochim Biophys Acta 1991;1086:173-184.
45. [45] Duchateau P, Rader D, Duverger N et al. Tangier disease: isolation and characterization of LpA-I, LpA-II, LpA-I:A-II and LpA-IV particles from plasma. Biochim Biophys Acta 1993;1182:30-36.
46. [46] Fielding CJ, Fielding PE. Molecular physiology of reverse cholesterol transport. J Lipid Res 1995;36:211-228.
47. [47] Huang Y, von Eckardstein A, Wu S, Maeda N, Assman G. A plasma lipoprotein containing only apolipoprotein E and with mobility on electrophoresis releases cholesterol from cells. Proc Natl Acad Sci USA 1994;91:1834-1838.
48. [48] Duverger N, Ghalim N, Ailhaud G, Steinmetz A, Fruchart J-C, Castro G. Characterization of apo A-IV-containing lipoprotein particles isolated from human plasma and interstitial fluid. Arterioscler Thromb 1991;13:126-132.
49. 3H)cholesterol efflux and uptake in cell culture. Biochim Biophys Acta 1995;1257:174-180.
50. [50] Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterification rates in very low density lipoprotein-and low density lipoprotein-depleted plasma: relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb 1991;11:64-70.
51. [51] Albers JJ, Chen CH, Adolphson JL. Lecithin:cholesterol acyltransferase (LCAT) mass; its relationship to LCAT activity and cholesterol esterification rate. J Lipid Res 1981;22:1206-1213.
52. [52] Kessling AM, Nanjee MN, Miller NE, Humphries SE. Variation in the apolipoprotein AI-CIII-AIV gene region and in lecithin:cholesterol acyltransferase concentration are determinants of plasma cholesterol concentrations. Atherosclerosis 1988;70:13-19.
53. [53] Williams PT, Albers JJ, Krauss RM, Wood PDS. Associations of lecithin:cholesterol acyltransferase (LCAT) mass concentrations with exercise, weight loss, and plasma lipoprotein subfraction concentrations in men. Atherosclerosis 1990;82:53-58.
54. [54] Glomset JA. The plasma lecithin:cholesterol acyltransferse reaction. J Lipid Res 1968;9:155-167.
55. [55] Kilsdonk EPC, Dorsman ANRD, van Tol A. Effect of LCAT on HDL-mediated cholesterol efflux from loaded EA.hy 926 cells. Int J Biochem 1993;25:219-221.
56. [56] Tu A-Y, Nishida HI, Nishida T. High density lipoprotein conversion mediated by human plasma phospholipid transfer protein. J Biol Chem 1993;268:23 098-23 105.
57. 1-HDL. Biochim Biophys Acta 1996;1301:255-262.